Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Neoplasms 5Uterine Cervical Neoplasms 3Breast Neoplasms 3Uterine Cervical Dysplasia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Precancerous Conditions 1Neoplasms by Site 1Neoplasm Metastasis 1Liver Neoplasms 1Leiomyosarcoma 1Leiomyoma 1Head and Neck Neoplasms 1Genital Neoplasms, Female 1Genital Diseases, Female 1Genital Diseases 1Female Urogenital Diseases and Pregnancy Complications 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adrenocortical Adenoma × Biopsy × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡